Novo Nordisk applies for label extension for diabetes treatment
Novo Nordisk will now also apply to the EU for a new and higher dose of the drug Ozempic, which is has already been approved for treating type 2 diabetes.
Novo Nordisk plans to expand its selection of doses in which the firm may sell the diabetes drug Ozempic. Recently, this resulted in an application to the European Medicines Agency for extending the current label, according to the company's press announcement.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo after crucial data from competitor: Welcomes drug R&D
For subscribers
